{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:14:53Z","timestamp":1757312093245,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00280-021-04323-0","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T09:02:58Z","timestamp":1627030978000},"page":"731-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study"],"prefix":"10.1007","volume":"88","author":[{"given":"Pritha","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0358-6476","authenticated-orcid":false,"given":"Satadru","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santanu","family":"Acharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandan","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partha","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"issue":"4","key":"4323_CR1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","volume":"29","author":"M Tahara","year":"2018","unstructured":"Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T (2018) Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol 29(4):1004\u20131009. https:\/\/doi.org\/10.1093\/annonc\/mdy040","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"4323_CR2","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.3747\/co.25.3954","volume":"25","author":"JM Lebert","year":"2018","unstructured":"Lebert JM, Lester R, Powell E, Seal M, McCarthy J (2018) Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 25(Suppl 1):S142\u2013S150. https:\/\/doi.org\/10.3747\/co.25.3954","journal-title":"Curr Oncol"},{"key":"4323_CR3","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045","journal-title":"J Clin Oncol"},{"key":"4323_CR4","unstructured":"https:\/\/www.nccn.org\/professionals\/OrderTemplates\/PDF\/appendix_B.pdf"},{"key":"4323_CR5","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"4323_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"4323_CR7","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/IGC.0b013e31822127ad","volume":"21","author":"IM Collins","year":"2011","unstructured":"Collins IM, Roberts-Thomson R, Faulkner D et al (2011) Carboplatin dosing in ovarian cancer: problems and pitfalls. Int J Gynecol Cancer 21:1213\u20131218. https:\/\/doi.org\/10.1097\/IGC.0b013e31822127ad","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"4323_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1177\/1078155218805136","volume":"25","author":"A Morrow","year":"2019","unstructured":"Morrow A, Garland C, Yang F, De Luna M, Herrington JD (2019) Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL\/min: To cap or not to cap? A retrospective analysis and review. J Oncol Pharm Pract 25(7):1651\u20131657. https:\/\/doi.org\/10.1177\/1078155218805136 (Epub 2018 Oct 18 )","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"4323_CR9","doi-asserted-by":"publisher","first-page":"e00320","DOI":"10.1136\/esmoopen-2018-000320","volume":"3","author":"M Fehr","year":"2018","unstructured":"Fehr M, Maranta AF, Reichegger H, Gillessen S, Cathomas R (2018) Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I. ESMO Open 3(3):e00320. https:\/\/doi.org\/10.1136\/esmoopen-2018-000320","journal-title":"ESMO Open"},{"key":"4323_CR10","unstructured":"Ahmed Wahba H, Ahmed El-Hadaad H. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med | v June | PMC4493381 Citations Cancer Biol Med. 2015"},{"key":"4323_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq279","author":"N Berrada","year":"2010","unstructured":"Berrada N, Delaloge S, Andr\u00e9 F (2010) Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdq279","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"4323_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000504","volume":"4","author":"R Caparica","year":"2019","unstructured":"Caparica R, Lambertini M, de Azambuja E (2019) How I treat metastatic triple-negative breast cancer. ESMO Open 4(Suppl 2):e000504. https:\/\/doi.org\/10.1136\/esmoopen-2019-000504","journal-title":"ESMO Open"},{"key":"4323_CR13","doi-asserted-by":"crossref","unstructured":"Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014","DOI":"10.1016\/S1470-2045(14)70160-3"},{"issue":"1","key":"4323_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1186\/s12885-019-6253-5","volume":"19","author":"JGP Pandy","year":"2019","unstructured":"Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF (2019) Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer 19(1):1065","journal-title":"BMC Cancer"},{"issue":"1","key":"4323_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/0284186X.2017.1407495","volume":"57","author":"LH Rosvig","year":"2018","unstructured":"Rosvig LH, Langkjer ST, Knoop A, Jensen AB (2018) Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer. Acta Oncol 57(1):156\u2013159. https:\/\/doi.org\/10.1080\/0284186X.2017.1407495","journal-title":"Acta Oncol"},{"issue":"17","key":"4323_CR16","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2217\/fon-2019-0059","volume":"15","author":"J Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s J, Andr\u00e9 F, Gon\u00e7alves A, K\u00fcmmel S, Mart\u00edn M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R (2019) IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol 15(17):1951\u20131961","journal-title":"Future Oncol"},{"issue":"4","key":"4323_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3802\/jgo.2014.25.4.355","volume":"25","author":"S Giovannoni","year":"2014","unstructured":"Giovannoni S, Trenta P (2014) Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration. J Gynecol Oncol 25(4):355\u2013356. https:\/\/doi.org\/10.3802\/jgo.2014.25.4.355","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"4323_CR18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O\u2019Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18(6):779\u2013791","journal-title":"Lancet Oncol"},{"key":"4323_CR19","doi-asserted-by":"publisher","unstructured":"Mirza MR, \u00c5vall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, \u00d8r Knudsen A, Staff S, Krog Vistisen A, Bj\u00f8rge L, M\u00e4enp\u00e4\u00e4 JU; AVANOVA investigators. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019 Oct;20(10):1409\u20131419. doi: https:\/\/doi.org\/10.1016\/S1470-2045(19)30515-7.","DOI":"10.1016\/S1470-2045(19)30515-7"},{"issue":"2 Suppl 1","key":"4323_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0749-2081(89)90083-1","volume":"5","author":"CH Yarbro","year":"1989","unstructured":"Yarbro CH (1989) Carboplatin: a clinical review. Semin Oncol Nurs 5(2 Suppl 1):63\u201369. https:\/\/doi.org\/10.1016\/0749-2081(89)90083-1","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"4323_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00003088-199733030-00002","volume":"33","author":"SB Duffull","year":"1997","unstructured":"Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33(3):161\u2013183","journal-title":"Clin Pharmacokinet"},{"key":"4323_CR22","unstructured":"Boyd LR, Muggia FM. Carboplatin\/Paclitaxel Induction in Ovarian Cancer: The Finer Points. Oncology (Williston Park). 2018 Aug 15;32(8):418\u201320, 422\u20134"},{"key":"4323_CR23","unstructured":"https:\/\/www.thehindu.com\/news\/cities\/Hyderabad\/ideal-body-weight-of-indian-men-now-65-kg-women-55-kg\/article32736299.ece"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04323-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T07:40:40Z","timestamp":1672904440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04323-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4323"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04323-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"6 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}